Recent Trends in Molecular Image-Guided Theranostic and Personalized Medicine

Dear Colleagues,

The sudden increase in the market for molecular imaging science enhances the opportunities to develop new molecular imaging agents for diagnosis and therapy. New clinical indications using the proteomic or genomic expression in oncology, cardiology, and neurology also offer a stimulus. This promotes the growth of procedure volume and sales of clinic imaging agents and the development of new radiopharmaceuticals. The growing use of molecular imaging is also helping to control and monitor dosage for increased safety and effectiveness. For instance, molecular imaging in oncology has been focused on identifying tumor-specific markers and applying these markers for the evaluation of patient response to radiation therapy, chemotherapy, or chemo/radiotherapy. Therefore, molecular imaging technologies play a significant role in providing personalized therapy for patients. The opportunity to use image-guiding to select a patient for personalized therapy is truly the focus. The imaging findings could be integrated with metabolomics. In addition, the theranostic concept is equally important in the personalized therapy of diseases. The effort in image-guided cell therapy theranostic approaches in parallel with instrumentation development would be more accurate in evaluating patient response to treatment. This Special Issue will provide new molecular imaging agents and instrumentation development trends. This Special Issue will become the scientific tool for moving a concept from bench work to clinic product development. This Special Issue will be interesting to translational research scientists and support staff, such as clinicians, molecular biologists, imaging scientists, pharmaceutical developers, physicists, fellows, and staff. Both academic and clinical scientists are invited to submit their manuscripts.
Potential topics include, but are not limited to: The image-guided theranostic approach of diseases. Advances in bioimaging applications in preclinical drug discovery. Advances in imaging instrumentation development. Hybrid imaging modalities in disease management. Theranostic agents development. Imaging technology in drug development. Validation of imaging agents on new molecular targets. Personalized drug development from molecular imaging. Link metabolomics and imaging molecular pathways. Treatment delivery using big radiomics analysis. Patient follow-up using big deep analysis. Patient diagnosis, assessment, and consultation in big data. Computer-aided detection and diagnosis. Treatment simulation using computer vision. Image registration/fusion. Image segmentation/auto-contouring. 

Dr. Muhammad Fazal Ijaz
Prof. Dr. Marcin Woźniak
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.